Developer docs
API playgroundTry for free, no card

Search company profiles

Northstrive Biosciences

Full company profile

uuid003mln8

Namestring
Northstrive Biosciences
Legal namestring
NorthStrive Biosciences, Inc.
Company typeenum
Private
Founded yearstring
-
Descriptiontext

NorthStrive Biosciences is a clinical-stage biopharmaceutical company developing engineered probiotic therapeutics that aim to preserve lean muscle mass during weight loss, with particular focus on patients using GLP-1 receptor agonists. The company's lead asset, EL-22, is an orally administered engineered Lactobacillus casei expressing modified human myostatin antigens that elicits an immune response producing anti-myostatin IgG antibodies, thereby inhibiting myostatin — a negative regulator of muscle growth. EL-22 has completed a Phase I study in 37 healthy adult volunteers in Seoul, South Korea, demonstrating a favorable safety and tolerability profile. A second candidate, EL-32, is a dual-action probiotic targeting both myostatin and activin-A pathways and entered a preclinical diet-induced obesity mouse model study in March 2026 to evaluate combination therapy with semaglutide.

The underlying technology combines microbiome engineering with immune-mediated protein inhibition, a mechanism distinct from direct antibody or small-molecule myostatin inhibitors. NorthStrive also pursues an AI-driven drug discovery program in collaboration with Yuva Biosciences (currently in Phase III validation), using classifier models to identify small-molecule candidates for mitochondrial health and muscle preservation. The company is filing aggressively on the IP side, with patent applications spanning human pharmaceutical indications (sarcopenia, muscle disuse atrophy, GLP-1-induced muscle loss) and animal health applications (livestock, aquaculture, poultry).

NorthStrive operates a dual-track business model. It retains human therapeutic rights internally and intends to monetize through licensing/royalty arrangements, milestones, and sublicensing. Animal health rights for EL-22 and EL-32 have already been licensed exclusively (excluding South Korea) to Modulant Biosciences, with NorthStrive receiving milestone payments and royalties on commercial sales. A separate licensing arrangement with Korean biotech MOA Life Plus covers human clinical development milestones. The company is pre-revenue on commercial product sales and is a wholly-owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB).

Short descriptiontext

NorthStrive Biosciences is a clinical-stage biopharmaceutical subsidiary of PMGC Holdings developing engineered probiotic therapeutics (EL-22, EL-32) that activate the immune system to preserve lean muscle mass during GLP-1 weight loss, monetizing via licensing and royalties.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewport Beach, United States
HQ citystring
Newport Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered probiotic therapeutics, muscle preservation biopharmaceuticals, obesity treatment development, clinical-stage biotech research, GLP-1 adjunct therapies
Industry1 code
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Animal Food Manufacturing31111
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Obesity Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

The company generates revenue through licensing agreements for its proprietary technologies. NorthStrive retains human therapeutic rights while licensing non-human animal health applications to partners. Revenue is expected from milestone payments, royalties on commercial sales, and sublicensing arrangements.

ng.investing.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NorthStrive Biosciences is a clinical-stage biopharmaceutical company developing engineered probiotic therapeutics for muscle preservation during weight loss treatments. Its lead candidate, EL-22, is an orally administered Lactobacillus casei engineered to express modified human myostatin antigens, eliciting anti-myostatin IgG antibodies to preserve lean muscle mass in patients on GLP-1 receptor agonists. A second candidate, EL-32, targets both myostatin and activin-A pathways. The company retains human therapeutic rights and licenses non-human animal health applications to partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase I clinical trial completed in 37 healthy adult volunteers showing good safety and tolerable profile
+1 more record
Product overview1 text field

NorthStrive Biosciences is a biopharmaceutical company developing a pipeline of engineered probiotic therapeutics targeting muscle preservation during weight loss treatments. The company's lead product is EL-22, a clinical-stage myostatin-inhibiting probiotic that has completed Phase 1 in healthy volunteers and is positioned for obesity treatment in combination with GLP-1 receptor agonists. EL-32 is a dual-action candidate targeting both myostatin and activin-A pathways. Both products leverage a novel mechanism of activating the body's own immune system to inhibit myostatin, addressing the significant muscle loss (up to 40% of weight loss) associated with GLP-1 drugs.

Product and service2 records
1EL-22
CategoryBiopharmaceutical Therapeutic
Description

Clinical-stage orally administered engineered probiotic (Lactobacillus casei) expressing modified human myostatin antigens. Activates the body's immune system to produce anti-myostatin IgG antibodies, preserving lean muscle mass during weight loss in patients on GLP-1 receptor agonists. For biopharmaceutical partners and future obesity patients.

2EL-32
CategoryBiopharmaceutical Therapeutic
Description

Dual-action engineered probiotic therapeutic targeting both myostatin and activin-A pathways for muscle preservation in patients undergoing GLP-1 receptor agonist weight loss therapy. Includes microorganism-based formulations involving lactic acid bacteria. For biopharmaceutical partners and obesity patients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Third amendment to licensing agreement with Korean biotech company MOA Life Plus to update development milestones for clinical programs EL-32 and EL-22. Development focuses on muscle preservation during weight loss treatments including GLP-1 receptor agonists. PMGC made a monetary payment upon execution of the amendment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

AI-driven drug discovery collaboration in Phase III validation stage. The program aims to validate small-molecule candidates targeting mitochondrial health and muscle preservation for obesity treatment. Results expected in Q2 2026 after Yuva deployed improved sixth-generation classifier models for more refined compound selection and comprehensive in-vitro validation.

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing therapeutics targeting the biology of aging, with active programs in obesity and muscle preservation. Comparable to NorthStrive in addressing muscle preservation during weight loss and metabolism, focused on small-molecule and biologic approaches.

TypeBroad incumbent
Description

Global pharmaceutical leader with Zepbound (tirzepatide) in the GLP-1 obesity market and active research into muscle-preserving combinations. Relevant as the dominant incumbent whose product NorthStrive's EL-22 is positioned to complement, and which could become either a licensing partner or competitive threat.

TypeBroad incumbent
Description

Manufacturer of Wegovy and Ozempic, the leading GLP-1 receptor agonists driving the muscle-loss concern NorthStrive addresses. Most relevant broad incumbent setting the standard of care that NorthStrive's adjunct therapeutic would pair with.

TypeEmerging player
Description

Clinical-stage biotech advancing VK2735, a dual GLP-1/GIP agonist for obesity. Comparable as an emerging obesity-focused player whose next-generation mechanisms could either compete with or create partnership opportunities for muscle-preservation combination therapies.

TypeDirect peer
Description

Clinical-stage biotech developing apitegromab, a leading myostatin-targeting antibody for muscle preservation. Directly comparable to NorthStrive in targeting the same myostatin pathway for muscle-wasting and obesity-related indications, with similar mechanism goals though delivered via injectable biologic rather than oral probiotic.

TypeEmerging player
Description

Developer of oral small-molecule GLP-1 receptor agonists for obesity. Comparable to NorthStrive in pursuing oral, needle-free alternatives in the obesity space, representing both a parallel innovation approach and a potential combination partner.

TypeEmerging player
Description

Animal health biotech using molecular farming to produce animal proteins in crops for livestock and aquaculture. Comparable to NorthStrive's animal health vertical where Modulant is developing EL-22/EL-32 for livestock, aquaculture, and poultry applications.

TypeBroad incumbent
Description

Major biotech with extensive antibody platform and historical work on myostatin-related pathways. Relevant as a broad incumbent with the resources and IP portfolio that could either compete with or partner around NorthStrive's muscle-preservation thesis.

TypeEmerging player
Description

Clinical-stage biotech developing engineered proteins targeting TGF-beta superfamily members including activin-A. Directly comparable to NorthStrive's EL-32 dual-action mechanism that targets both myostatin and activin-A pathways for muscle preservation.

TypeEmerging player
Description

Biopharmaceutical company developing protein therapeutics with proprietary manufacturing platforms. Comparable to NorthStrive in the biologic/protein therapeutic space and in advancing novel biologics through clinical development, though focused on pulmonary and rare diseases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Northstrive Biosciences

Obesity Biopharmaceuticalsnorthstrivebio.com

NorthStrive Biosciences is a clinical-stage biopharmaceutical subsidiary of PMGC Holdings developing engineered probiotic therapeutics (EL-22, EL-32) that activate the immune system to preserve lean muscle mass during GLP-1 weight loss, monetizing via licensing and royalties.

What Northstrive Biosciences does

NorthStrive Biosciences is a clinical-stage biopharmaceutical company developing engineered probiotic therapeutics that aim to preserve lean muscle mass during weight loss, with particular focus on patients using GLP-1 receptor agonists. The company's lead asset, EL-22, is an orally administered engineered Lactobacillus casei expressing modified human myostatin antigens that elicits an immune response producing anti-myostatin IgG antibodies, thereby inhibiting myostatin — a negative regulator of muscle growth. EL-22 has completed a Phase I study in 37 healthy adult volunteers in Seoul, South Korea, demonstrating a favorable safety and tolerability profile. A second candidate, EL-32, is a dual-action probiotic targeting both myostatin and activin-A pathways and entered a preclinical diet-induced obesity mouse model study in March 2026 to evaluate combination therapy with semaglutide.

The underlying technology combines microbiome engineering with immune-mediated protein inhibition, a mechanism distinct from direct antibody or small-molecule myostatin inhibitors. NorthStrive also pursues an AI-driven drug discovery program in collaboration with Yuva Biosciences (currently in Phase III validation), using classifier models to identify small-molecule candidates for mitochondrial health and muscle preservation. The company is filing aggressively on the IP side, with patent applications spanning human pharmaceutical indications (sarcopenia, muscle disuse atrophy, GLP-1-induced muscle loss) and animal health applications (livestock, aquaculture, poultry).

NorthStrive operates a dual-track business model. It retains human therapeutic rights internally and intends to monetize through licensing/royalty arrangements, milestones, and sublicensing. Animal health rights for EL-22 and EL-32 have already been licensed exclusively (excluding South Korea) to Modulant Biosciences, with NorthStrive receiving milestone payments and royalties on commercial sales. A separate licensing arrangement with Korean biotech MOA Life Plus covers human clinical development milestones. The company is pre-revenue on commercial product sales and is a wholly-owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB).

Northstrive Biosciences firmographics

Firmographics
Name
Northstrive Biosciences
Legal name
NorthStrive Biosciences, Inc.
Website
https://northstrivebio.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
NorthStrive Biosciences is a clinical-stage biopharmaceutical subsidiary of PMGC Holdings developing engineered probiotic therapeutics (EL-22, EL-32) that activate the immune system to preserve lean muscle mass during GLP-1 weight loss, monetizing via licensing and royalties.
Ownership category
akta.pro rank

Northstrive Biosciences industry classification

Industry
Product category
Obesity Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Animal Food Manufacturing (31111)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)

Keywords

  • Engineered probiotic therapeutics
  • Muscle preservation biopharmaceuticals
  • Obesity treatment development
  • Clinical-stage biotech research
  • GLP-1 adjunct therapies

Where Northstrive Biosciences is headquartered

Location

Headquarters

HQ city
Newport Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Northstrive Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Licensing and Royalty Revenue: The company generates revenue through licensing agreements for its proprietary technologies. NorthStrive retains human therapeutic rights while licensing non-human animal health applications to partners. Revenue is expected from milestone payments, royalties on commercial sales, and sublicensing arrangements.

Go-to-market motion1 record

Marketing channels2 records

Northstrive Biosciences product offering

Product offering

Core offering

NorthStrive Biosciences is a clinical-stage biopharmaceutical company developing engineered probiotic therapeutics for muscle preservation during weight loss treatments. Its lead candidate, EL-22, is an orally administered Lactobacillus casei engineered to express modified human myostatin antigens, eliciting anti-myostatin IgG antibodies to preserve lean muscle mass in patients on GLP-1 receptor agonists. A second candidate, EL-32, targets both myostatin and activin-A pathways. The company retains human therapeutic rights and licenses non-human animal health applications to partners.

Product overview

NorthStrive Biosciences is a biopharmaceutical company developing a pipeline of engineered probiotic therapeutics targeting muscle preservation during weight loss treatments. The company's lead product is EL-22, a clinical-stage myostatin-inhibiting probiotic that has completed Phase 1 in healthy volunteers and is positioned for obesity treatment in combination with GLP-1 receptor agonists. EL-32 is a dual-action candidate targeting both myostatin and activin-A pathways. Both products leverage a novel mechanism of activating the body's own immune system to inhibit myostatin, addressing the significant muscle loss (up to 40% of weight loss) associated with GLP-1 drugs.

Differentiator

Problem solved

Functional benefit

Products and services

  • EL-22 Clinical-stage orally administered engineered probiotic (Lactobacillus casei) expressing modified human myostatin antigens. Activates the body's immune system to produce anti-myostatin IgG antibodies, preserving lean muscle mass during weight loss in patients on GLP-1 receptor agonists. For biopharmaceutical partners and future obesity patients.
  • EL-32 Dual-action engineered probiotic therapeutic targeting both myostatin and activin-A pathways for muscle preservation in patients undergoing GLP-1 receptor agonist weight loss therapy. Includes microorganism-based formulations involving lactic acid bacteria. For biopharmaceutical partners and obesity patients.

Quantifiable outcome

  • Phase I clinical trial completed in 37 healthy adult volunteers showing good safety and tolerable profile
  • +1 more outcomes

Companies that use Northstrive Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Northstrive Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Northstrive Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • MOA Life Plus Co., Ltd.coreStrategic or Co-development Partner · 27 March 2026Third amendment to licensing agreement with Korean biotech company MOA Life Plus to update development milestones for clinical programs EL-32 and EL-22. Development focuses on muscle preservation during weight loss treatments including GLP-1 receptor agonists. PMGC made a monetary payment upon execution of the amendment.
  • Yuva BiosciencescoreStrategic or Co-development Partner · 17 December 2025AI-driven drug discovery collaboration in Phase III validation stage. The program aims to validate small-molecule candidates targeting mitochondrial health and muscle preservation for obesity treatment. Results expected in Q2 2026 after Yuva deployed improved sixth-generation classifier models for more refined compound selection and comprehensive in-vitro validation.

Scale indicators4 records

Expansion highlights5 records

Northstrive Biosciences competitors and assessment

Company assessment

Direct peers

  • BioAge Labs: Clinical-stage company developing therapeutics targeting the biology of aging, with active programs in obesity and muscle preservation. Comparable to NorthStrive in addressing muscle preservation during weight loss and metabolism, focused on small-molecule and biologic approaches.
  • Scholar Rock: Clinical-stage biotech developing apitegromab, a leading myostatin-targeting antibody for muscle preservation. Directly comparable to NorthStrive in targeting the same myostatin pathway for muscle-wasting and obesity-related indications, with similar mechanism goals though delivered via injectable biologic rather than oral probiotic.

Broad incumbents

  • Eli Lilly: Global pharmaceutical leader with Zepbound (tirzepatide) in the GLP-1 obesity market and active research into muscle-preserving combinations. Relevant as the dominant incumbent whose product NorthStrive's EL-22 is positioned to complement, and which could become either a licensing partner or competitive threat.
  • Novo Nordisk: Manufacturer of Wegovy and Ozempic, the leading GLP-1 receptor agonists driving the muscle-loss concern NorthStrive addresses. Most relevant broad incumbent setting the standard of care that NorthStrive's adjunct therapeutic would pair with.
  • Regeneron Pharmaceuticals: Major biotech with extensive antibody platform and historical work on myostatin-related pathways. Relevant as a broad incumbent with the resources and IP portfolio that could either compete with or partner around NorthStrive's muscle-preservation thesis.

Emerging players

  • Viking Therapeutics: Clinical-stage biotech advancing VK2735, a dual GLP-1/GIP agonist for obesity. Comparable as an emerging obesity-focused player whose next-generation mechanisms could either compete with or create partnership opportunities for muscle-preservation combination therapies.
  • Structure Therapeutics: Developer of oral small-molecule GLP-1 receptor agonists for obesity. Comparable to NorthStrive in pursuing oral, needle-free alternatives in the obesity space, representing both a parallel innovation approach and a potential combination partner.
  • Moolec Science: Animal health biotech using molecular farming to produce animal proteins in crops for livestock and aquaculture. Comparable to NorthStrive's animal health vertical where Modulant is developing EL-22/EL-32 for livestock, aquaculture, and poultry applications.
  • Keros Therapeutics: Clinical-stage biotech developing engineered proteins targeting TGF-beta superfamily members including activin-A. Directly comparable to NorthStrive's EL-32 dual-action mechanism that targets both myostatin and activin-A pathways for muscle preservation.
  • Insmed Incorporated: Biopharmaceutical company developing protein therapeutics with proprietary manufacturing platforms. Comparable to NorthStrive in the biologic/protein therapeutic space and in advancing novel biologics through clinical development, though focused on pulmonary and rare diseases.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Northstrive Biosciences social profiles

Digital presence

Northstrive Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Northstrive Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Northstrive Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Northstrive Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Northstrive Biosciences

What does Northstrive Biosciences do?

NorthStrive Biosciences is a clinical-stage biopharmaceutical company developing engineered probiotic therapeutics for muscle preservation during weight loss treatments. Its lead candidate, EL-22, is an orally administered Lactobacillus casei engineered to express modified human myostatin antigens, eliciting anti-myostatin IgG antibodies to preserve lean muscle mass in patients on GLP-1 receptor agonists. A second candidate, EL-32, targets both myostatin and activin-A pathways. The company retains human therapeutic rights and licenses non-human animal health applications to partners.

Is Northstrive Biosciences a public or private company?

Northstrive Biosciences is a private company. It is classified as corporate owned and is currently operating.

When was Northstrive Biosciences founded?

Northstrive Biosciences was founded in -1. It employs 1 to 10 people.

Where is Northstrive Biosciences based?

Northstrive Biosciences is headquartered in Newport Beach, United States, in the North America region.

How does Northstrive Biosciences make money?

One revenue line is on record: licensing and Royalty Revenue.

Who are Northstrive Biosciences's main competitors?

Direct peers on record are BioAge Labs and Scholar Rock. Broad incumbents are Eli Lilly, Novo Nordisk and Regeneron Pharmaceuticals. Emerging players are Viking Therapeutics, Structure Therapeutics, Moolec Science, Keros Therapeutics and Insmed Incorporated.

Does Northstrive Biosciences have an API?

No public API is recorded for Northstrive Biosciences.

What industry is Northstrive Biosciences in?

Northstrive Biosciences's product category is Obesity Biopharmaceuticals. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyProbiotic combined with semaglutide preserves lean muscle in obesity studyNorthStrive Biosciences completed an eight-week preclinical study of its engineered probiotic EL-32 combined with semaglutide in diet-induced obesity mice. The highest EL-32 dose with semaglutide showed greater absolute lean mass and improved glucose response, but no consistent additive metabolic benefit. The company plans a follow-on preclinical study on lean mass and body composition, with an update expected in Q1 2027.Business & FinancialNorthstrive Biosciences Announces Results From EL-32 Preclinical Combination Study With Semaglutide And Plans For Next Phase Of DevelopmentNorthStrive Biosciences completed an eight-week preclinical study of EL-32 with semaglutide in a mouse model, finding greater lean mass at the highest dose and improved glucose response at the lowest dose. The company plans a follow-on study with a lower semaglutide dose, targeting lean mass and body composition as primary endpoints, with an update expected in Q1 2027.FinancialContent Business PageNorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of DevelopmentNorthStrive Biosciences completed an eight-week preclinical study of EL-32 with semaglutide in a diet-induced obesity mouse model. The high-dose combination showed greater weight reduction and improved insulin sensitivity, but no significant lean-mass difference. NorthStrive plans a follow-on study with a lower semaglutide dose, with an update expected in Q1 2027.GlobeNewswireNorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of DevelopmentNorthStrive Biosciences completed an eight-week preclinical study of EL-32 with semaglutide in a mouse model, finding greater lean mass at the highest EL-32 dose and improved glucose response at the lowest combination dose. The company plans a follow-on study with a lower semaglutide dose, targeting lean mass and body composition as primary endpoints, with an update expected in Q1 2027.Stock TitanNorthStrive Biosciences EL-32 study finds lean-mass signalNorthStrive Biosciences reported results from an eight-week mouse study of EL-32 with semaglutide, finding greater weight loss and improved insulin sensitivity. The highest EL-32 dose showed a statistically significant greater difference in body weight gain, but no significant difference in relative lean mass. The company plans a follow-on study with a lower semaglutide dose, with an update expected in Q1 2027.Quiver QuantitativePMGC Subsidiary NorthStrive Biosciences Engages Charles River Laboratories for Analytical Characterization of EL-22 and EL-32 Programs | ELAB Stock NewsPMGC Holdings subsidiary NorthStrive Biosciences engaged Charles River Laboratories to perform analytical characterization of its engineered probiotics EL-22 and EL-32, focusing on plasmid copy number analysis. The work aims to support product identity and manufacturing consistency as the programs advance toward an IND-enabling development framework.Stock TitanNorthStrive Biosciences signs testing deal with Charles RiverNorthStrive Biosciences signed a Statement of Work with Charles River Laboratories to conduct analytical characterization of its EL-22 and EL-32 engineered probiotic programs. The work will measure plasmid copy numbers using nucleic-acid amplification and fluorescent-probe technology at Charles River's U.S. Biologics Testing sites. The data aims to support product identity, manufacturing consistency, and comparability as the programs advance toward an IND-enabling development framework.FinancialContent Business PageNorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic ProgramsNorthStrive Biosciences signed a Statement of Work with Charles River Laboratories to conduct analytical characterization of its EL-22 and EL-32 engineered probiotic programs. The work will measure plasmid copy numbers using nucleic-acid amplification and fluorescent-probe technology at Charles River's U.S. Biologics Testing sites. The data aims to support product identity and manufacturing consistency as the programs advance toward an IND-enabling development framework.Longevity.TechnologyAI narrows four muscle-saving drugs to oneNorthStrive Biosciences expanded its partnership with Yuva Biosciences to test four AI-discovered compounds for preserving muscle during weight loss. The six-month program aims to narrow candidates to a single lead, with a right of first refusal in cardiometabolic disease. The approach targets mitochondrial function in skeletal muscle.Quiver QuantitativePMGC Holdings Announces Interest-Bearing Payment Agreement Securing NorthStrive Biosciences’ Royalty Cash Flows Through 2031 | ELAB Stock NewsPMGC Holdings announced an interest-bearing payment agreement with Longevity Health Holdings to convert a 5% net sales royalty from its Elevai Skincare divestiture into scheduled monthly cash payments to NorthStrive Biosciences through August 2031. The first $10,000 installment begins October 15, 2026, creating non-dilutive recurring cash flow.